EUVIMEDSkopri EUVIMED
Open access

The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study

Chachrit Khunsriraksakul, Olivia Ziegler iD, Dajiang Liu, Audrey S Kulaylat, Matthew D Coates iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70147 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Chachrit Khunsriraksakul and 4 co-authors. Institution: Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA. Major MEDLINE topics: Analgesics, Opioid, Abdominal Pain, Inflammatory Bowel Diseases, Parasympatholytics. Cited 5 times so far (Crossref); 23 references. The full text is freely available in PubMed Central. Funded by: NLM NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Patients with inflammatory bowel disease (IBD) are often prescribed antispasmodics for chronic abdominal pain. Large‐scale data regarding efficacy and impact on clinical outcomes are lacking.

Aim

To examine the association between antispasmodic use and outcomes of abdominal pain and opioid use before and after propensity matching key demographic and clinical characteristics.

Methods

We used TriNetX Diamond Network, a medical and claims database. Patients were stratified by baseline abdominal pain and opioid use. Secondary outcomes were corticosteroid use, IBD‐related complications and surgeries, emergency room (ER) visits, hospitalisation and mortality.

Results

We included 85,859 patients (median age 50; 53.8% female) with IBD; 5661 used antispasmodics. On follow‐up, those with antispasmodic use had higher rates of abdominal pain and opioid use ( p < 0.001) regardless of baseline abdominal pain or opioid use. After matching, 5629 patients remained per group. Patients who used antispasmodics had higher rates of abdominal pain at 1 month, regardless of baseline abdominal pain. Opioid‐naïve patients who used antispasmodics had higher rates of opioid use at follow‐up (1.1% vs. 0.2%; p < 0.001). The likelihood of corticosteroid use, clinic visits, ER visits and hospitalisation were higher in those with antispasmodic use. No differences in IBD‐related complications, surgery or mortality were observed.

Conclusions

Antispasmodic use in patients with IBD was associated with increased abdominal pain and opioid use in opioid‐naïve patients. Antispasmodic use was associated with increased likelihood of corticosteroid use, clinic and ER visits and hospitalisation.

Subjects

MeSH terms (MEDLINE)

Analgesics, OpioidAbdominal PainInflammatory Bowel DiseasesParasympatholyticsHumansFemaleMaleMiddle AgedAdultAgedAdrenal Cortex HormonesTreatment Outcome

Author keywords

antispasmodicsinflammatory bowel diseaseirritable bowel syndromeopioidspain management

Substances

Analgesics, OpioidParasympatholyticsAdrenal Cortex Hormones

Authors and institutions

  • Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA.
  • Medical Scientist Training Program, Penn State College of Medicine, Hershey, Pennsylvania, USA.
  • Department of General Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA.
  • Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
  • Division of Colon and Rectal Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA.
  • Division of Gastroenterology and Hepatology, Penn State College of Medicine, Hershey, Pennsylvania, USA.

ORCID profiles: Olivia Ziegler, Matthew D Coates

Funding

  • NLM NIH HHS
  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Khunsriraksakul, C., Ziegler, O., Liu, D., Kulaylat, A. S., & Coates, M. D. (2025). The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70147

Vancouver

Khunsriraksakul C, Ziegler O, Liu D, Kulaylat AS, Coates MD. The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70147

BibTeX
@article{Khunsriraksakul2025,
  author = {Khunsriraksakul, Chachrit and Ziegler, Olivia and Liu, Dajiang and Kulaylat, Audrey S and Coates, Matthew D},
  title = {The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70147}
}
Start for free →